Lung cancer can stay dormant for years It can take 20 years for the cancer to turn into an aggressive form of the disease; this is the conclusion of two studies by Cancer Research and The Rosetrees Trust. 7 patients took part in the study, including smokers, ex-smokers and never smokers. Better ways to detect the disease are needed earlier. Patients are diagnosed with advanced forms of the disease when treatments are less likely to be successful. To read more http://www.sciencedaily.com/releases/2014/10/141009154007.htm Special points of interest This bulletin is free to Interested people in Pharma & Healthcare Please send names of new subscribers to [email protected]If you have articles, comments or story ideas, please send them to the email above www.wavedata.co.uk Commercial Bulletin Monthly service October 14 Inside this issue Lung cancer can stay dor- mant for years Scotland given finding for new medicines Drug sent to Africa for Ebola by Chinese Pharma- ceutical Company Visiting you local pharma- cist could save the NHS £1bn PRICE WATCH ............ UK - September brings a tale of two sartans Dispensing Doctor Dis- pensing Fee Rises from October 1 st 2014 Forthcoming events Mind the patient gap WaveData — Top ten searched products where the focus was to September 2014 Scotland given finding for new medicines To improve access to new medicines for rare diseases, the Scottish government has been given double funding, from 20 million to 40 million. It will help to access greater research, which will ultimately bring new hope for pa- tients with incurable rare diseases. The money will be made available by a newly-established new medicines fund. In 2103/14, 45 different drugs where supported by the funding, which 200 patients were able to benefit from. To read more http://www.bbc.co.uk/news/uk-scotland-scotland-politics-29516363
Transcript
Lung cancer can stay dormant for years It can take 20 years for the cancer to turn into an aggressive form of the disease; this is the conclusion of two studies by Cancer Research and The Rosetrees Trust. 7 patients took part in the study, including smokers, ex-smokers and never smokers. Better ways to detect the disease are needed earlier. Patients are diagnosed with advanced forms of the disease when treatments are less likely to be successful. To read more http://www.sciencedaily.com/releases/2014/10/141009154007.htm
PRICE WATCH ............ UK - September brings a tale of
two sartans
Dispensing Doctor Dis-pensing Fee Rises from
October 1st 2014
Forthcoming events
Mind the patient gap
WaveData — Top ten searched products where the focus was to September
2014
Scotland given finding for new medicines To improve access to new medicines for rare diseases, the Scottish government has been given double funding, from 20 million to 40 million. It will help to access greater research, which will ultimately bring new hope for pa-tients with incurable rare diseases. The money will be made available by a newly-established new medicines fund. In 2103/14, 45 different drugs where supported by the funding, which 200 patients were able to benefit from. To read more http://www.bbc.co.uk/news/uk-scotland-scotland-politics-29516363
Drug sent to Africa for Ebola by Chinese Pharmaceutical Company
A Chinese pharmaceutical company with military ties has sent an experimental Ebola drug to Africa for use
by Chinese aid workers, along with African victims.
The companies are planning clinical trials there to combat the disease.
Governments and pharma companies from around the world have been racing to find a treatment for the out-
PRICE WATCH ............ UK September brings a tale of two sartans Valsartan 40mg, 80mg and 160mg capsules were again on the monthly price concession list of the Department of Health in September, allowing pharmacists and dispensing doctors to claim far more in reimbursement than the offi-cial Drug Tariff prices (Generics bulletin, 19 September 2014, page 23). Prices for candesartan 8mg tablets, however, fell by double-digit amounts. The lowest price slumped by 16%, reversing a trend of the previous month (Generics bulletin, 5 September 2014, page 25). Meanwhile, the average price of candesartan 8mg tablets dropped by 10% to £0.89 (US$1.45), an order of magnitude less than the average price of £10.03 for valsartan 80mg capsules, which were granted a concessionary reimbursement price of £10.80 (see Figure 1).alsartan 40mg, 80mg and 160mg cap-sules were again on the monthly price concession list of the Department of Health in September, allowing pharmacists and dispensing doctors to claim far more in reimbursement than the official Drug Tariff prices (Generics bulletin, 19 September 2014, page 23). Prices for candesartan 8mg tablets, however, fell by double-digit amounts. The lowest priceslumped by 16%, reversing a trend of the previous month (Generics bulletin, 5 September 2014, page 25). Meanwhile, the average price of candesartan 8mg tablets dropped by 10% to £0.89 (US$1.45), an morder of magni-tude less than the average price of £10.03 for valsartan 80mg capsules, which were granted a concessionary reim-bursement price of £10.80 (see Figure 1).
To see more go to http://www.wavedata.co.uk/newinfo.asp and view our article from this month’s Generics Bulletin.
WaveData
Subscribe to the industry's comprehensive source of news and analysis.
www.generics-bulletin.com
P a g e 2 C o m m e r c i a l B u l l e t i n
Visiting your local pharmacist could save the NHS £1bn
Research has shown that if patients were to go to see their local community pharmacists rather than their GP for minor ailments, the NHS could save £1bn. This would also cut down on the waiting time for patients with the more serious conditions, allowing them to see their GP earlier. Patients who visit their local GP or A&E for minor ailments still received the same outcome as they would by visiting their local pharmacists. To read more http://www.bbc.co.uk/news/uk-29679559
P a g e 3 O c t o b e r 1 4
Dispensing Doctor Dispensing Fee Rises from October 1st 2014
It was recently announced that the dispensing fee for dispensing doctors was going to rise from October 1st 2014 for England and Wales. This uplift will make the dispensing of low cost generic medicines more profitable on a % gross profit basis where the Drug Tariff reimbursement is low for dispensing doctor practices. Recent reimbursement price falls due to Category M and other factors have led to a drop in income for many dispens-ing doctors. At the time of writing the dispensing fee for retail pharmacies remains at £0.90 for most medicines dispensed. [See Drug Tariff October 2014 Part IIIA for full details of pharmacy reimbursement]. The full dispensing fee scale is now:
For more information on dispensing doctors please email [email protected] www.surelines.co.uk
Feescale from 1st of October 2014
Total prescriptions calculated separately for each individual dispensing practitioner, in bands
Up to 449 £2.19
450-560 £2.16
561-673 £2.13
674-785 £2.11
786-898 £2.08
899-1009 £2.06
1010-1402 £2.04
1403-1962 £2.02
1963-2243 £2.00
2244-2804 £1.98
2805-3364 £1.97
3365-3925 £1.96
3926-4485 £1.95
4486 and over £1.94
Organizer Date Venue Link or Email
ABHI Annual Conference 4th Nov 2014 London http://www.sbrihealthcare.co.uk/
UCL Partners Workshop 'Value of Technology on Healthcare' 6th Nov 2014 London http://www.uclpartners.com/events/the-value-of-technology-in-healthcare-2014
AAPS Annual Meeting & Exposition Nov-14 San Diego www.ccra.org.uk/meetings/futureEvents.asp
17th Annual IGPA Conference 19-21 Nov 2014 Miami, US www.igpagenerics.com/17th-annual-igpa-conference-19-21-november-2014
EMIG Conference 'How is Specialised Commissioning Developing in the NHS?
25th November 2014
London www.emig.org.uk
Roboleo & Co training seminar 2nd December 2014
Berkshire www.roboleo.com
NHS England – SBRI Healthcare Innovation Expo 10th December 2014
London http://www.sbrihealthcare.co.uk/
14th EGA Regulatory and Scientific Affairs Conference 22-23 January 2015
London www.egagenerics.com
Forthcoming events
Mind the patient gap
Society needs the caring professions more than ever. The ONS predicts that an ageing workforce will be the most significant develop-ment in the UK labour market over the next 6 years. They forecast that by 2020 over one third of the UK workforce will be aged over 50. However, an older workforce is more likely to get sick. In 2013, 131 million working days were lost to sickness. In the future, with an older workforce, illness could have a serious impact on the economy and society. The health industry can make a real difference. The NHS is already one of the most cost-effective public health systems in the world, but, with ever tighter budgets the health industry as a whole needs to find another productivity gear if it is to continue to care for society without bankrupting it. One place to start looking for productivity gains is in the ‘Patient Gap’. This is the cost to society of poorer outcomes, increased care costs and reduced economic activity that derives from the low engagement of patients in their healthcare. It is a cost that comes from missed appointments through to increased time in hospital due to non-compliance. In the UK, NESTA estimates that more engaged patients could save the NHS at least £4.4bn annually, enough to pay for over 150,000 nurses. Whilst in the USA, poor compliance is estimated to cost $100bn a year and is responsible for as many as two thirds of hospital admissions. It seems counterintuitive that the people who have most to gain from adherence are so disengaged, but the compliance rates for even those with the most chronic and disabling of illnesses are terrifyingly low. One study measured an adherence rate of just 50% amongst people at risk of blindness due to Glaucoma. The reasons for poor compliance are because we are human: we put things off, we are forgetful, we would rather take short cuts and avoid uncomfortable experiences even if they are good for us in the long run. So if we are to close the patient gap we need to under-stand better the human element in healthcare. That means having more and deeper insight into the lives and motivations of patients, physicians, carers and even employers. Better understanding of how treatments fit into patient’s lives means we can design more en-gaging and effective treatment experiences for them. However, a study amongst senior marketing pharma executives revealed that 0% of them considered gathering meaningful patient insight to be a top 7 priority. When we benchmarked Pharma comapanies against Retail and Professional Services firms we found that customer insight was far more highly prized in the latter industries as a tool for developing strategies . This is worrying. It suggests that much of the talk about patient centricity in Annual Reports is not yet translating into culture, investment and incentives within many organisations. Closing the Patient Gap is an opportunity for every part of the healthcare industry. Drug companies can engage their health consumers in the design of more intuitive and flexible treatment experiences. Physicians can create consultations that provide more “sticky” ad-vice and tools that enable patients to put that advice into practice. Hospitals can provide more joined up services. Insurers and Gov-ernments can provide more incentives for employers and the public to get healthy and actively prevent illnesses. The rapid growth in everything from ‘Quantified Self’ applications to nutritional supplements shows that many people are motivated to be more engaged and take more control of their health. We just haven’t yet uncovered the insights that will unlock motivation and engagement in the wider population. This is the start of an exciting new era in healthcare, where prevention and compliance will be key to the achieving the efficiencies necessary to combat spiraling costs. In this new start, the healthcare industry that has been so successful up until now in caring for us will need to become just a little bit more understanding.
James Osmond is CEO of Clear, the global marketing strategy consultancy division of M&C Saatchi.
ONS Labour market projections 2006-2020 NHS LiveWell: Boost Your Health at Work NESTA: The Business case for people powered health, 2013. Osterberg and Blasche: Adherence in Medication, 2005 Okeke CO et al: Adherence with Topical Glaucoma Medication Monitored Electronically Clear: Cost of Change Study, 2013 Clear: Cost of Change Study, 2013 www.Clear-ideas.com
P a g e 4 C o m m e r c i a l B u l l e t i n
This bulletin now goes out to 3900 plus people.
If you would like to add or suggest any articles/comments, please let me know by the 12th November 2014, as I will be issuing the next one on the 19th November.
2014
If you have any colleagues who would like to receive this, please let them know about it.
You can view all copies of the Bulletin at http://www.wavedata.co.uk/newinfo.asp
![GLEN OSMOND MENU.pptx [Read-Only] - Chopstix …chopstixrestaurants.com.au/.../09/GLEN-OSMOND-MENU.pdf · Title: Microsoft PowerPoint - GLEN OSMOND MENU.pptx [Read-Only] Author: Asim](https://static.documents.pub/doc/80x56/5ae02f927f8b9a97518ceb1b/glen-osmond-menupptx-read-only-chopstix-microsoft-powerpoint-glen-osmond.jpg)
